Literature DB >> 24692596

Immunoresolving actions of oral resolvin D1 include selective regulation of the transcription machinery in resolution-phase mouse macrophages.

Antonio Recchiuti1, Marilina Codagnone2, Anna Maria Pierdomenico3, Cosmo Rossi4, Veronica Cecilia Mari4, Eleonora Cianci3, Felice Simiele2, Valentina Gatta5, Mario Romano2.   

Abstract

Resolvin D1 (RvD1; 7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid) is an endogenous immunoresolvent that regulates acute inflammation and orchestrates resolution. Here, we investigated anti-inflammatory and proresolving actions of RvD1 after oral administration. RvD1 rapidly accumulated in the mouse plasma after oral delivery and dose-dependently (1-100 ng/mouse) reduced leukocyte infiltration in zymosan A-induced acute peritonitis. Using mathematical resolution indices, RvD1 reduced Ψmax by ∼50%, shortened the resolution interval by 3 h, and significantly reduced total leukocyte (by ∼30-45%) and polymorphonuclear neutrophil (by ∼40-55%) accumulation when administered at the peak of peritonitis. RvD1 also improved course and outcome of severe peritonitis, shifting it toward resolution. In peritoneal macrophages (MΦs) from the resolution phase of peritonitis, RvD1 down-regulated (by 2- to 3-fold) select genes that control gene transcription, namely coactivator-associated arginine methyltransferase 1 (CARM1), and downstream genes, such as colony-stimulating factor 3, intercellular adhesion molecule 1, and monocyte inflammatory protein 2, which promote neutrophil infiltration and reduce MΦ phagocytosis. Congruently, CARM1 knockdown in human and murine MΦs induced a proresolving phenotype, recapitulating in vivo actions of RvD1. These results establish novel properties of RvD1 and demonstrate that RvD1 modifies the transcription control machinery in MΦs, as part of its mechanisms of action during the resolution of acute inflammation.-Recchiuti, A., Codagnone, M., Pierdomenico, A. M., Rossi, C., Mari, V. C., Cianci, E., Simiele, F., Gatta, V., Romano, M. Immunoresolving actions of oral resolvin D1 include selective regulation of the transcription machinery in resolution-phase mouse macrophages. © FASEB.

Entities:  

Keywords:  chromatin-remodeling enzymes; docosahexaenoic acid; pharmacology

Mesh:

Substances:

Year:  2014        PMID: 24692596     DOI: 10.1096/fj.13-248393

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  22 in total

1.  Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements.

Authors:  Melinda S Schaller; Greg J Zahner; Warren J Gasper; William S Harris; Michael S Conte; Nancy K Hills; S Marlene Grenon
Journal:  J Clin Lipidol       Date:  2017-06-24       Impact factor: 4.766

2.  Resolvin D1, resolvin D2 and maresin 1 activate the GSK3β anti-inflammatory axis in TLR4-engaged human monocytes.

Authors:  Zhen Gu; Gwyneth J Lamont; Richard J Lamont; Silvia M Uriarte; Huizhi Wang; David A Scott
Journal:  Innate Immun       Date:  2016-02-15       Impact factor: 2.680

3.  Resolution of sickle cell disease-associated inflammation and tissue damage with 17R-resolvin D1.

Authors:  Alessandro Matte; Antonio Recchiuti; Enrica Federti; Bérengère Koehl; Thomas Mintz; Wassim El Nemer; Pierre-Louis Tharaux; Valentine Brousse; Immacolata Andolfo; Alessia Lamolinara; Olga Weinberg; Angela Siciliano; Paul C Norris; Ian R Riley; Achille Iolascon; Charles N Serhan; Carlo Brugnara; Lucia De Franceschi
Journal:  Blood       Date:  2018-11-07       Impact factor: 22.113

4.  MicroRNA-181b regulates ALX/FPR2 receptor expression and proresolution signaling in human macrophages.

Authors:  Anna Maria Pierdomenico; Antonio Recchiuti; Felice Simiele; Marilina Codagnone; Veronica Cecilia Mari; Giovanni Davì; Mario Romano
Journal:  J Biol Chem       Date:  2014-12-11       Impact factor: 5.157

Review 5.  Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors.

Authors:  Nan Chiang; Charles N Serhan
Journal:  Mol Aspects Med       Date:  2017-03-31

Review 6.  Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.

Authors:  Charles N Serhan; Bruce D Levy
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

7.  Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection.

Authors:  M Codagnone; E Cianci; A Lamolinara; V C Mari; A Nespoli; E Isopi; D Mattoscio; M Arita; A Bragonzi; M Iezzi; M Romano; A Recchiuti
Journal:  Mucosal Immunol       Date:  2017-04-19       Impact factor: 7.313

8.  Oral Resolvin D1 attenuates early inflammation but not intimal hyperplasia in a rat carotid angioplasty model.

Authors:  Giorgio Mottola; Evan C Werlin; Bian Wu; Mian Chen; Anuran Chatterjee; Melinda S Schaller; Michael S Conte
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-12-10       Impact factor: 3.072

9.  Bioactive products formed in humans from fish oils.

Authors:  Carsten Skarke; Naji Alamuddin; John A Lawson; Xuanwen Li; Jane F Ferguson; Muredach P Reilly; Garret A FitzGerald
Journal:  J Lipid Res       Date:  2015-07-15       Impact factor: 5.922

10.  Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis.

Authors:  Laila M Poisson; Hamid Suhail; Jaspreet Singh; Indrani Datta; Aleksandar Denic; Krzysztof Labuzek; Md Nasrul Hoda; Ashray Shankar; Ashok Kumar; Mirela Cerghet; Stanton Elias; Robert P Mohney; Moses Rodriguez; Ramandeep Rattan; Ashutosh K Mangalam; Shailendra Giri
Journal:  J Biol Chem       Date:  2015-11-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.